New product Jaros

Hey there!

We wanted to let everyone know that we just released a new product called Jaros! The active ingredient is tirzepatide. 

Here's a little info about tirzepatide:

Tirzepatide is a new type of medication used to help people lose weight, treat obesity, and manage diabetes.

 

It's a dual receptor agonist (GIP and GLP-1), which is different from Ozempic, which is an agonist of only GLP-1.

 

The FDA (USA) officially approved the drug in 2022 for treating obesity and type 2 diabetes. It was approved in Europe in 2023.

 

A double strike against obesity:

 

GLP-1 receptors get activated, which suppresses glucagon secretion, raises blood sugar levels, slows down how fast food leaves your stomach, which means glucose enters the bloodstream more slowly. It also affects the satiety centers in the hypothalamus, reducing appetite and increasing the feeling of fullness. This helps you lose weight.

 

GIP receptors are activated (this is the main difference from GLP-1–only analogues):it makes the effects of GLP-1 stronger and improves how fat cells (adipocytes) metabolize fat.

 

This has a combined effect:

 

The combo of two mechanisms in a single molecule has a stronger effect on blood glucose levels and body weight compared to drugs like semaglutide and liraglutide that only have GLP-1.

The dosage range is from 2.5 to 15 mg per week.

Our Jaros has 15 mg in a vial, and we sell extra water for injection with it.

You can find the product in the Fat Burning section on our website.